Disease modifying therapies delay disease progression
17 January 2019
International study results show that DMTs significantly decrease the probability of converting from relapsing remitting MS to secondary progressive MS.
International study results show that DMTs significantly decrease the probability of converting from relapsing remitting MS to secondary progressive MS.
The results of an observational trial into AHSCT in Sydney have been released showing good results for some people with relapsing-remitting MS.
How does MS begin? There has been ongoing debate in the scientific world around the so called “outside-in” or “inside-out” question.
Three times more women than men are diagnosed with MS in Australia, so what is the role of sex hormones in MS?
Professor Michael Pender explains more about the anti-EBV treatment ‘adoptive T cell immunotherapy’ that has shown promise for people with progressive MS in his clinical trial.
World-first clinical trial shows new anti-EBV treatment appears safe and may help progressive MS.
New research has shown that certain genes control disease course of MS. Three genetic changes have been identified that may relate to aggressive or mild MS.
The widespread cognitive and emotional symptoms experienced by people with neurological diseases, including MS, has been highlighted by new Australian research.
There has been an explosion of reports about potential myelin repair therapies, so what does it all mean? How close are